Shionogi

News

Shionogi takes Akili’s ADHD digital therapy to Japan

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype

News

Shionogi agrees $140m deal to buy antibiotic biotech Qpex

While most pharma companies have exited the antibiotics area, Japanese dru

News

FDA says no to F2G’s novel antifungal

F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candi

News

Shionogi starts pivotal Japanese trial of Akili's ADHD app

A Japanese language version of Akili Interactive's EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results d

News

Hand in glove holding Petri plate with bacteria Steptococcus Phaemolifticus G, Streptococcus Agalactiae, Streptococcus Phaemolifticus

UK launches its 'Netflix-style' payment model for antibiotic...

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category.

News